1. Home
  2. BTAI vs JG Comparison

BTAI vs JG Comparison

Compare BTAI & JG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • JG
  • Stock Information
  • Founded
  • BTAI 2017
  • JG 2012
  • Country
  • BTAI United States
  • JG China
  • Employees
  • BTAI N/A
  • JG N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • JG Computer Software: Programming Data Processing
  • Sector
  • BTAI Health Care
  • JG Technology
  • Exchange
  • BTAI Nasdaq
  • JG Nasdaq
  • Market Cap
  • BTAI 48.3M
  • JG 48.4M
  • IPO Year
  • BTAI 2018
  • JG 2018
  • Fundamental
  • Price
  • BTAI $2.07
  • JG $7.84
  • Analyst Decision
  • BTAI Buy
  • JG
  • Analyst Count
  • BTAI 5
  • JG 0
  • Target Price
  • BTAI $32.80
  • JG N/A
  • AVG Volume (30 Days)
  • BTAI 1.0M
  • JG 6.9K
  • Earning Date
  • BTAI 11-13-2025
  • JG 11-13-2025
  • Dividend Yield
  • BTAI N/A
  • JG N/A
  • EPS Growth
  • BTAI N/A
  • JG N/A
  • EPS
  • BTAI N/A
  • JG N/A
  • Revenue
  • BTAI $868,000.00
  • JG $48,999,972.00
  • Revenue This Year
  • BTAI N/A
  • JG $10.90
  • Revenue Next Year
  • BTAI $614.78
  • JG N/A
  • P/E Ratio
  • BTAI N/A
  • JG N/A
  • Revenue Growth
  • BTAI N/A
  • JG 18.82
  • 52 Week Low
  • BTAI $1.17
  • JG $4.25
  • 52 Week High
  • BTAI $13.28
  • JG $20.94
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 34.40
  • JG 37.37
  • Support Level
  • BTAI $2.14
  • JG $8.08
  • Resistance Level
  • BTAI $2.46
  • JG $8.55
  • Average True Range (ATR)
  • BTAI 0.17
  • JG 0.28
  • MACD
  • BTAI 0.00
  • JG 0.00
  • Stochastic Oscillator
  • BTAI 2.64
  • JG 27.73

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About JG Aurora Mobile Limited

Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.

Share on Social Networks: